Deeks, Steven G.
Archin, Nancie
Cannon, Paula http://orcid.org/0000-0003-0059-354X
Collins, Simon
Jones, R. Brad
de Jong, Marein A. W. P.
Lambotte, Olivier
Lamplough, Rosanne
Ndung’u, Thumbi
Sugarman, Jeremy http://orcid.org/0000-0001-7022-8332
Tiemessen, Caroline T. http://orcid.org/0000-0002-0991-1690
Vandekerckhove, Linos http://orcid.org/0000-0002-8600-1631
Lewin, Sharon R. http://orcid.org/0000-0002-0330-8241
Deeks, Steven
Lewin, Sharon
de Jong, Marein
Ndhlovu, Zaza
Chomont, Nicolas
Brumme, Zabrina
Deng, Kai
Jasenosky, Luke
Jefferys, Richard
Orta-Resendiz, Aurelio
Mardarelli, Frank
Nijhuis, Monique
Bar, Katharine
Howell, Bonnie
Schneider, Alex
Turk, Gabriela
Nabatanzi, Rose
Blankson, Joel
Garcia, J. Victor
Paiardini, Mirko
Lunzen, Jan van
Antoniadi, Christina
Côrtes, Fernanda Heloise
Valente, Susana
Søgaard, Ole S.
Diaz, Ricardo Sobhie
Ott, Melannie
Dunham, Richard
Schwarze, Siegfried
Patrigeon, Santiago Perez
Nabukenya, Josephine
Caskey, Marina
Mothe, Beatriz
Wang, Fu Sheng
Fidler, Sarah
SenGupta, Devi
Dressler, Stephan
Matoga, Mitch
Kiem, Hans-Peter
Tebas, Pablo
Kityo, Cissy
Dropulic, Boro
Louella, Michael
Das, Kumitaa Theva
Persaud, Deborah
Chahroudi, Ann
Luzuriaga, Katherine
Puthanakit, Thanyawee
Safrit, Jeffrey
Masheto, Gaerolwe
Dubé, Karine
Power, Jennifer
Salzwedel, Jessica
Likhitwonnawut, Udom
Taylor, Jeff
Nuh, Oguzhan Latif
Dong, Krista
Kankaka, Edward Nelson
,
,
,
,
,
,
,
,
,
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 12 September 2021
Accepted: 27 October 2021
First Online: 1 December 2021
Competing interests
: S.G.D. receives research support from Gilead and Merck. He is a member of the scientific advisory boards for BryoLogyx, Enochian Biosciences and Tendel. He has consulted for AbbVie, Biotron, Eli Lilly, GSK/ViiV and Immunocore; J.S. is a member of Merck KGaA’s Ethics Advisory Panel and Stem Cell Research Oversight Committee; a member of IQVIA’s Ethics Advisory Panel; a member of Aspen Neurosciences Clinical Advisory Panel; a member of a Merck Data Monitoring Committee; a consultant to Biogen; and a consultant to Portola Pharmaceuticals Inc. None of these activities are related to the issues discussed in this manuscript; T.N. has received research funding from Gilead Sciences; O.L. has been paid expert testimony and consultancy fees from BMS France, MSD, Astra Zeneca; consultancy fees from Incyte, Sobi, grants from ViiV and Gilead; L.V. receives research grants from J&J, ViiV Healthcare and Gilead Sciences; P.C. is a member of Gilead’s HIV Cure Advisory Board; S.R.L.’s institution receives funding for investigator initiated research from Gilead, Merck and Viiv. She has research collaborations with BMS, Abbvie and Merck. She has received honoraria paid to her for membership of advisory boards to Gilead, Merck, Viiv, Immunocore, Vaxxinity, Biotron, Esfam and Abivax; R.L. is an employee of the International AIDS Society; M.d.J. was paid as a consultant by the International AIDS Society. S.C., R.B.J., C.T. and N.A. have no interests to declare.
Free to read: This content has been made available to all.